StockTake: Orthocell
Orthocell has appointed the first four US distributors for its flagship nerve repair product Remplir.
Orthocell has appointed the first four US distributors for its flagship nerve repair product Remplir.
Good morning! Here’s everything you need to know, and some things you don’t, before the ASX flings open its doors and begins trading today.
Victory Metals has received a US$190 million letter of interest from the Export-Import Bank of the United States.
Koonenberry finds visible gold in the fifth diamond hole at its prospective Enmore project in the New England Fold Belt of NSW.
Tariffs set by US President Donald Trump have upset the global economy but Pure Hydrogen believes it can leverage them to its benefit.
RareX and Iluka will team up in a bid to ride a wave of positive sentiment for rare earths together at a Kenyan project.
Wall Street cops another hit after Trump gives Powell another spray, gold and the Aussie dollar bounce, Yancoal sounds the alarm.
Trump’s gone off at Powell again, rattling markets, but the ASX held its nerve with banks and miners stepping up.
Recce Pharmaceuticals receives Human Research Ethics Committee approval to expand its phase II clinical trial following positive results.
Fund flows reveal market sentiment, giving a clear picture of whether investors are feeling confident and taking risks or playing it safe.
A lithium supply deficit could see an aggressive move in pricing as soon as 2026. We look at North American players who could benefit.
The hardest part of the junior exploration game is funding. But Kincora Copper is showing how to multiply the cash you have to play with.
Original URL: https://www.couriermail.com.au/business/stockhead/page/3